300 Years of GSK Three Centuries of Innovation

Total Page:16

File Type:pdf, Size:1020Kb

300 Years of GSK Three Centuries of Innovation 300 years of GSK Three centuries of innovation 1 715 1 848 1880 1883 1 891 Plough Court Pharmacy Thomas Beecham launches Burroughs Wellcome The Horlick brothers patent the Smith, Kline & Company acquires 1 830 1 884 established in London John K Smith and his the Beecham’s Pills business & Company established process of purifying and drying Burroughs Wellcome French, Richards and Company. by Silvanus Bevan, brother-in-law open a drugstore in England. By the early twentieth in London by pharmacists milk with malt, a product that & Company registers The original company that John which later becomes in Philadelphia, which would century, production is at one Henry Wellcome and later becomes known as ‘Tabloid’ as a trademark K Smith founded went through Allen & Hanburys Ltd. later become Smith, million pills per day. Silas Burroughs. Horlicks Malted Milk. to describe its numerous name and ownership Kline & Company. compressed changes before becoming Smith, tablets. Kline & French Company. 1 969 1 944 1936 1906 1 894 Ventolin launched by By mid-1944, 80% of the UK’s Wellcome Trust’s first ‘Glaxo’ trademark Wellcome Physiological Allen & Hanburys as penicillin doses are routed chairman Sir Henry Dale is registered. Research Labs established, 1972 a treatment for asthma. through Glaxo Laboratories’ wins Nobel Prize in Joseph Nathan & Co. Ltd. focused on biological Medicine. 1 924 Amoxycillin discovered. Greenford site. Sir John Vane Joseph Nathan & Co. realised that selling dried milk experimentation including early forms of vaccines. Scientists at Beecham (1982) and George launches its first as an infant food called for a Research Laboratories Hitchings, Gertrude Elion pharmaceutical product, more appealing name than Defiance, discover amoxycillin and Sir James Black (1988) a vitamin D supplement the name used in 1981 and launch Amoxil, later win the same award. called Ostelin. New Zealand. They started Zovirax launched for viral which will become with Lacto, and by adding and herpes infections, one of an antibiotic staple. changing letters, the name many life-saving drugs rationally Glaxo was born. designed by Hitchings and Elion. 1988 2 000 2 004 Zantac by Glaxo becomes Merger of Glaxo Wellcome and Clinical Trial Register launched. 1 987 the world’s biggest prescription 1995 SmithKline Beecham creates GSK is the first company to A new medicine Retrovir (AZT) Glaxo and Wellcome merge to drug for stomach ulcers. GlaxoSmithKline plc, known launch an online site of clinical by Wellcome becomes the first form Glaxo Wellcome plc., the as GSK. A year later, we acquire trial data accessible to all. approved treatment for AIDs. world’s largest pharmaceutical company. Block Drug Co. adding a wider range of consumer products to 1 989 1998 our portfolio. Merger of SmithKline Beckman SmithKline Beecham and the and the Beecham Group to form World Health Organization join SmithKline Beecham plc. forces to eliminate lymphatic filariasis (elephantiasis) by the year 2020. 2018 2017 2016 2 014 2012 2 009 To support advances in the GSK launches three new Sensodyne becomes 2015 Phase III trial concludes for the GSK is an official supplier to Stiefel acquired and development of new medicines, products: Shingrix, a vaccine GSK’s first consumer brand Major 3-part transaction world’s first malaria vaccine the London 2012 Olympic and ViiV Healthcare launched. GSK embarks on a major research to help prevent shingles in to reach £1bn in sales. with Novartis. candidate, RTS,S. The pilot Paralympic Games, providing 2011 GSK becomes a leader in initiative to sequence genetic people aged 50 or older; GSK and Novartis create joint implementation will begin in official laboratory services for Human Genome Sciences skincare with the acquisition data from 500,000 volunteer triple therapy inhaler Trelegy Consumer Healthcare venture. Ghana, Kenya and Malawi. anti-doping measures. and GSK receive approval of Stiefel. GSK and Pfizer launch participants in the UK Biobank Ellipta, for patients with GSK acquires the Novartis for Benlysta, the first new ViiV Healthcare, a company healthcare resource. COPD; and Juluca, the first global Vaccines business and lupus treatment in focused on delivering advances 2-drug regimen for people divests its marketed Oncology 50 years. in treatment and care for living with HIV. portfolio business to Novartis. HIV communities..
Recommended publications
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Dovato, INN-Dolutegravir, Lamivudine
    26 April 2019 EMA/267082/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Dovato International non-proprietary name: dolutegravir / lamivudine Procedure No. EMEA/H/C/004909/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Downloaded from wizmed.com Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Biologic features ...............................................................................................
    [Show full text]
  • Second Quarter 2017
    Press release Second quarter 2017 Issued: Wednesday, 26 July 2017, London U.K. GSK delivers further progress in Q2 and sets out new priorities for the Group Q2 sales of £7.3 billion, +12% AER, +3% CER Total loss per share of 3.7p, +59% AER, +29% CER; Adjusted EPS of 27.2p, +12% AER, -2% CER Financial highlights • Pharmaceutical sales, £4.4 billion, +12% AER, +3% CER, Vaccines sales, £1.1 billion, +16% AER, +5% CER, Consumer Healthcare sales, £1.9 billion,+10% AER, flat at CER • Group operating margin 28.5%; Pharmaceuticals 33.6%; Vaccines 33.7%; Consumer 17.7% • Total Q2 loss per share of 3.7p reflecting charges resulting from increases in the valuation of Consumer and HIV businesses and new portfolio choices • Updated 2017 guidance: Adjusted EPS growth now expected to be 3% to 5% CER reflecting impact of Priority Review Voucher • H1 Free Cash Flow £0.4 billion (H1 2016: £0.1 billion) • 19p dividend declared for Q2; continue to expect 80p for FY 2017 Product and pipeline highlights • New product sales of £1.7 billion, +62% AER, +47% CER • HIV two drug regimen (dolutegravir and rilpivirine) filed for approval in US and EU • Shingrix filed for approval in Japan • FDA approval received for subcutaneous Benlysta for treatment of SLE New business priorities to 2020 • New priorities to strengthen innovation, improve performance and build trust • Pharmaceutical R&D pipeline reviewed with target over time to allocate 80% of capital to priority assets in two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation)
    [Show full text]
  • PEDIARIX Is a Vaccine
    HIGHLIGHTS OF PRESCRIBING INFORMATION • If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior These highlights do not include all the information needed to use vaccine containing tetanus toxoid, the decision to give PEDIARIX should PEDIARIX safely and effectively. See full prescribing information for be based on potential benefits and risks. (5.2) PEDIARIX. • The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.3) PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis • Syncope (fainting) can occur in association with administration of Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus injectable vaccines, including PEDIARIX. Procedures should be in place Vaccine], Suspension for Intramuscular Injection to avoid falling injury and to restore cerebral perfusion following Initial U.S. Approval: 2002 syncope. (5.4) • If temperature ≥105°F, collapse or shock-like state, or persistent, ----------------------------- INDICATIONS AND USAGE ---------------------------- PEDIARIX is a vaccine indicated for active immunization against diphtheria, inconsolable crying lasting ≥3 hours have occurred within 48 hours after tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, receipt of a pertussis-containing vaccine, or if seizures have occurred and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants within 3 days after receipt of a pertussis-containing vaccine, the decision born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX to give PEDIARIX should be based on potential benefits and risks. (5.5) may be given as early as 6 weeks of age through 6 years of age (prior to the • For children at higher risk for seizures, an antipyretic may be 7th birthday).
    [Show full text]
  • Glaxosmithkline Bangladesh Limited (GSK)
    GlaxoSmithKline Bangladesh Limited (GSK) Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation nd Date of Submission: 2 September, 2014 ©Daffodil International University DAFFODIL INTERNATIONAL UNIVERSITY Internship Report On Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation Submitted To Dr. Zakir Hossain Dean& Professor Faculty of Business & Economics Daffodil International University Submitted By Ishrat Jahan ID: 131-14-1019 Masters of Business Administration Daffodil International University Date of Submission: 2nd September, 2014 ©Daffodil International University Letter of Transmittal September 2, 2014 To Dr. Zakir Hossain Dean & Professor Faculty of Business and Economics Daffodil International University Dhaka-1205 Subject: Submission of internship report on recruitment and selection process: An evaluation of GlaxoSmithKline Bangladesh Limited Sir, I am highly satisfied to submit my report on recruitment and selection process: an evaluation of GSK. For preparing this report I tried my best to accumulate relevant and upgraded information from available sources. In preparing this report, I tried my level best to make it a complete one and sincerely look forward to any possible correction. I am very glad because you also given the opportunity to prepare this report .I hope that this report will meet the standards of your judgments. Your Sincerely ---------------- Ishrat Jahan ©Daffodil International University i Certificate of the Supervisor This is to certify that the internship report titled ―Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation‖, has been prepared by Ms. Ishrat Jahan bearing ID: 131-14-1019 under my supervision, a practical study on GlaxoSmithKline Bangladesh Limited. I think on the basic of declaration Ms.
    [Show full text]
  • EMJ-5.2-2020-4.Pdf
    Contents + EDITORIAL BOARD 4 + CONGRESS REVIEW Review of the European Conference on Rare Diseases, 10 15th – 16th May 2020 + FEATURE The COVID-19 Conundrum and Cancer – Making Perfect Sense of 19 Imperfect Data Utkarsh Acharya + SYMPOSIUM REVIEW Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative 22 Colitis: The Missing Piece of The Puzzle? + POSTER REVIEWS Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction 29 of Atherosclerotic Cardiovascular Disease Events Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent 37 Real-World Data + INTERVIEWS Data from the AUGUSTUS Trial Adds an Important Piece to the 42 Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Renato D. Lopes and Amit N. Vora Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: 47 An Expert Clinical Consensus Vallerie McLaughlin and Sean Gaine 2 EMJ • June 2020 • Cover Image © Anna Grigorjeva / 123rf.com EMJ “It is more important than ever that information is disseminated rapidly and responsibly in the face of such global threats” Spencer Gore, CEO + ARTICLES Editor's Pick: Bone-Related Markers of Cardiovascular Disease 54 Ernesto Maddaloni et al. National Institute for Health and Care Excellence (NICE) Guidelines on 63 Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management Rhys H. Thomas and Jacob Brolly The Role of Next-Generation Sequencing and Reduced Time to 76 Diagnosis In Haematological Diseases: Status Quo and Prospective Overview of Promising Molecular Testing Approaches Christina Ranft Bernasconi et al. Sebaceous Carcinoma: A Rare Extraocular Presentation of the Cheek 85 Ritu Swali et al.
    [Show full text]
  • Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation
    CLINICAL PHARMACOLOGY IN THE UK, c. 1950–2000: INDUSTRY AND REGULATION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 25 September 2007 Edited by L A Reynolds and E M Tansey Volume 34 2008 ©The Trustee of the Wellcome Trust, London, 2008 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2008 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 118 9 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and L A Reynolds ix Introduction Professor Parveen Kumar xxiii Transcript Edited by L A Reynolds and E M Tansey 1 References 73 Biographical notes 89 Glossary 103 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. Reproduced by permission of AstraZeneca. 6 Figure 2 A summary of the organization of clinical trials. Adapted from www.clinicaltrials.gov/ct2/info/glossary (visited 1 May 2008). 10 Figure 3 Clinical trial certificates (CTC) and clinical trial exemption (CTX), 1972–1985. Adapted from Speirs (1983) and Speirs (1984).
    [Show full text]
  • Final Attendee List
    Jennifer Abnet GlaxoSmithKline I GlaxoSmithKline I Jane Arboleda APRN Guardant I Molly Benson Sanjiv Agarwala MD Puma Biotechnology I Cancer Expert Now I Joe Arminger AbbVie I Seth Berkowitz LCSW, Manmeet Ahluwalia MD, CCLS MBA Patricia Armstrong The Leukemia & Lymphoma Miami Cancer Institute I Novartis I Society V Steve Albers Kim Arnold APRN CPNP Barry Berman MD, MS Alexion V CPHON Florida Cancer Specialists I Servier Pharmaceuticals I Maritza Alencar DNP, Tizano Bernard MBA, APRN, BMTCN Sheila Arrington MSN, Cancer Care Centers of Miami Cancer Institute V APRN, NP-C, AOCN Brevard I Puma Biotechnology I Carmen Allen MSIT Ana Mari Bernardini Pharmavoxx V Shannon Ashmon Novartis Oncology I Eisai, Inc I Luly Almeida Bernard Berry MBA Incyte Corporation I Sarah Ashton MS AstraZeneca Pharmaceuticals Guardant Health I I Talat Almukhtar MD Orlando Health Cancer Melissa Austin Jason Bever Institute I Cancer Care Centers of Oncopeptides I Brevard I Beatrice Alvarado Roberts Amy Bignon MD Garland Avera Doyle Caris Life Sciences I University of Florida I Jazz Pharmaceuticals I Nadeem Bilani MD Tadeu Ambros MD Francie Babcock Cleveland Clinic I FCS I AMAG Pharmaceuticals/Covis I Angela Bilik RN BSN Douglas Anderson AstraZeneca I Incyte Corporation I Craig Bailey Astra Zeneca I Jamie Bilsky BS Blesson Andrews Genentech V Genentech I Kevin Barr Daiichi Sankyo I Rohit Bishnoi MD Ollie Annum PharmD University of Florida I BHMCR I Leonard Bennett PharmD EMD Serono I Brady Blackman Susmitha Apuri MD MorphoSys I Florida Cancer Specialists I Michael Bennett As of 4-22-21 Kimberly Blandon RN MSN Rick Breitenstein Memorial Cancer Institute I Apellis Pharmaceuticals I Denise Capo Karyopharm Therapeutics I Taryn Boiteau GlaxoSmithKline I Amanda Bridges Florida Society of Clinical Heidi Caravetta Tracy Bonds RN, BSN, Oncology I Exelixis, Inc.
    [Show full text]
  • Wellcome Four Year Phd Programme in Integrative Cell Mechanisms
    2021 Wellcome Four Year PhD Programme in Integrative Cell Mechanisms Training the next generation of Molecular Cell Biologists Background and Aims of Programme The Wellcome Four Year PhD Programme in Integrative Cell Mechanisms (iCM) is closely associated with the Wellcome Centre for Cell Biology and trains the next generation of cell and molecular biologists in the application of quantitative methods to understand the inner workings of distinct cell types in different settings. A detailed understanding of normal cellular function is required to investigate the molecular cause of disease and design future treatments. However, data generated by biological research requires increasingly complex analysis with technological advances in sequencing, mass spectrometry/proteomics, super-resolution microscopy, Wellcome Centre for Cell Biology 2021 synthetic and structural biology generating increasingly large, complex datasets. In addition, innovations in computer sciences and informatics are transforming data acquisition and analysis and breakthroughs in physics, chemistry and engineering allow the development of devices, molecules and instruments that drive the biological data revolution. Exploiting technological advances to transform our understanding of cellular mechanisms will require scientists who have been trained across the distinct disciplines of natural sciences, engineering, informatics and mathematics. To address this training need, iCM PhD projects are cross-disciplinary involving two primary supervisors with complementary expertise. Supervisor partnerships pair quantitative scientists with cell biologists ensuring that students develop pioneering cross-disciplinary collaborative projects to uncover cellular mechanisms relevant to health and disease. We aim to recruit students with a variety of backgrounds across the biological and physical sciences, including Biochemistry, Biomedical Science, Cell Biology, Chemistry, Computational Data Sciences, Engineering, Genetics, Mathematics, Molecular Biology and Physics.
    [Show full text]
  • The Everyday Lives of Recovering Heroin Users
    The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering The everyday lives of recovering heroin users The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering Joanne Neale Professor of Public Health Faculty of Health & Life Sciences Oxford Brookes University Jack Straw’s Lane Marston Oxford OX3 0FL Email: [email protected] Sarah Nettleton Reader in Sociology Department of Sociology Wentworth College University of York Heslington York YO10 5DD Email: [email protected] Lucy Pickering Lecturer in Anthropology School of Social and Political Sciences University of Glasgow Adam Smith Building Glasgow G12 8RT Email: [email protected] Published by the RSA 8 John Adam Street London WC2N 6EZ +44 (0)20 7930 5115 Registered as a charity in England and Wales no. 212424 and in Scotland no. SCO 37784 Copyright © Joanne Neale 2012 The RSA is an enlightenment organisation devoted to finding innovative and practical solutions to today’s pressing social problems Cover photo: ‘Wings of butterfly,’ John Foxx. © Thinkstock Designed by Soapbox, www.soapbox.co.uk Printed and bound by CPI Antony Rowe www.theRSA.org Contents Acknowledgements 9 Foreword 10 Chapter 1: Setting the scene 14 Why read this book? 14 Why focus on recovery? 15 What is recovery? 15 A study of the everyday lives of recovering heroin users 17 Structure of the book 18 Chapter 2: Considering recovery 20 Introduction 20 Mapping services and support 20 Factors that can encourage and sustain recovery efforts
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • A Case Study of Glaxosmithkline Plc )
    )l GROWTH THROUGH MERGER: A CASE STUDY OF GLAXOSMITHKLINE PLC ) / BY JUNE WANGARI UNIVERSITY OF NAIR03J LOWER KABETE LIBRARY A MANAGEMENT RESEARCH PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF MASTER OF BUSINESS ADMINISTRATION (MBA), SCHOOL OF BUSINESS, UNIVERSITY OF NAIROBI JULY, 2008 DECLARATION I declare that this project is my original work and has never been presented for academic purposes in any other University. CANDIDATE: JUNE WANGARI DATE .(.91. This research project has been submitted for examination with my approval as the University Supervisor SIGNED. DATE. Prof. Evans Aosa Department Of Business Administration, School Of Business, University Of Nairobi 11 DEDICATION I dedicate this project to my daughter Jemima, who was born within the first year of my post graduate studies. And now that she is in kindergarten, I see that I have instilled in her the love for reading and learning and I trust that she will go very far. iii ACKNOWLEDGEMENT I thank God for seeing me through my studies as I tried to balance between my family, my work and my studies. I wish to acknowledge the contributions that were made in the course of this project by several individuals and organizations. I wish to acknowledge gratefully the following people, whose effort influenced the content and direction of this project. My first thanks go to my Supervisor Prof. Evans Aosa for his constant analytical criticism and encouragement. Thanks a lot. I wish to thank my friends for a lot of support and encouragement to me in pursuit of this goal.
    [Show full text]